What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · ABBV

AbbVie bets $10.9 billion on new skin drugs — buy the pharma giant on the dip

Drug giant AbbVie just announced a massive $10.9 billion deal to buy a smaller biotech company called Apogee Therapeutics. AbbVie is buying them specifically to get their hands on new skin disease treatments.

Idea

AbbVie is using its massive cash reserves to buy next-generation skin treatments, a smart move to replace revenue as some of their older top-selling drugs face new competition. Big acquisitions like this usually signal that the acquiring company's management is confident in their financial future and wants to keep growing. Since AbbVie is a giant, stable pharmaceutical company, buying on any temporary dip caused by the acquisition announcement offers a relatively safe way to benefit from their expanded drug lineup.

Key details

ABBVD1#M&A#pharma#large_cap_defensive

Community

Upvotes

Views

Copies

Cosigns

News sources

AbbVie to Buy Apogee Therapeutics for $10.9 Billion — Bloomberg
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push — CNBC

Related ideas

Vertex drops $10B to dominate hormone treatments — ride the acquisition momentum